Bolt Biotherapeutics Business Summary

Bolt Biotherapeutics, Inc. (BOLT) is a clinical-stage biopharmaceutical company that generates revenue primarily through strategic R&D collaborations and licensing agreements, notably with partners such as Genmab and Toray. The company operates within the immuno-oncology segment, leveraging its proprietary Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) platform to develop therapies that engage both the innate and adaptive immune systems. Its current pipeline is centered on BDC-4182, a next-generation ISAC targeting Claudin 18.2, and BDC-3042, a first-in-class Dectin-2 agonist antibody. In a highly competitive landscape populated by major players like Amgen, Gilead Sciences, and Zymeworks, Bolt differentiates itself by focusing on myeloid-mediated immune activation to convert "cold" tumors into "hot" ones, aiming for more durable clinical responses than traditional cytotoxic antibody-drug conjugates. Founded in 2015 by Dr. Edgar G. Engleman of Stanford University, the company is led by President and CEO Willie Quinn, who previously served as the firm's CFO and brought extensive biopharma operational experience upon succeeding Randal Schatzman in 2024. The executive team includes Grant Yonehiro as Chief Operating Officer, Michael N. Alonso, Ph.D. (Co-founder) as Senior Vice President of Research, and Dawn Colburn, Pharm.D. as Senior Vice President of Clinical Development. Financial oversight is managed by Sarah Nemec, Senior Vice President of Finance and Principal Accounting Officer. The company is governed by a board chaired by Brian O'Callaghan and backed by prominent life science investors including Sofinnova Investments, Pivotal bioVenture Partners, and Nan Fung Life Sciences.